<DOC>
	<DOCNO>NCT00767663</DOCNO>
	<brief_summary>In study investigator investigate whether short pretreatment ( 3-7 day ) dipyridamole 200mg twice daily protect patient myocardial injury sustain elective dotter operation coronary artery ( PCI ) . The investigator hypothesize dipyridamole reduce myocardial injury sustain elective PCI .</brief_summary>
	<brief_title>Persantin Preceding Elective PCI</brief_title>
	<detailed_description>Rationale : In elective PCI ( percutaneous coronary intervention ) 40 % patient show asymptomatic rise myonecrosis marker troponin-I . This release troponin-I find represent irreversible myocardial injury relate increase risk restenosis even long-term mortality . Dipyridamole proven induce protection ischemia reperfusion injury reduce risk cardiovascular death event secondary prevention TIA CVA . Objective : To test hypothesis dipyridamole improve tolerance ischemia reperfusion injury patient undergo elective PCI . Study design : Double-blind placebo control intervention study Study population : Patients undergo elective PCI Intervention : pretreatment dipyridamole ( Persantin Retard ) 2dd 200mg placebo . Main study parameter : Periprocedural troponin-I release measure 8 hour PCI . Bioequivalence study : start th clinical trial perform bioequivalent study test whether study medication ( blinded recapsuling ) equal original dipyridamole capsule . 6 Healthy volunteer cross-over randomise design take original dipyridamole 200 mg SR recapsuled dipyridamole 200mg SR ( prepared department pharmacy RUNMC ) . Plasma dipyridamole concentration measure frequently baseline 1 3 hour administration dipyridamole nucleoside transport inhibition erythrocytes measure , assess drug activity . The clinical trial initialize conformation bioequivalence study medication original dipyridamole .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Dipyridamole</mesh_term>
	<criteria>Patients accept elective single , native vessel ( left anterior descending , right coronary artery ramus circumflexus ( LAD , RCA RCX ) ) PCI RUNMC TroponinI &lt; 0,20 mmol/L screening Signed Informed consent unstable angina recent myocardial infarction ( STEMI nonSTEMI ) , two week prior inclusion 3Vessel disease see coronary angiogram Stenotic lesion main stem see coronary angiogram CABG medical history asthma ( recurrent episode dyspnoea wheeze , usage prescribe inhalation medication : i.e . corticosteroid B2agonists ) Treatment insulin Use prescribe oral anticoagulant ( coumarin derivates ) Use oral corticosteroid Use sulfonylurea derivates ( glibenclamide , tolbutamide , gliclazide , glimepiride ) Use heparin low molecular weight heparin Use metformin Use dipyridamole Chronic use Non Steroid AntiInflammatory Drugs ( NSAID 's )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>